ERNEST HAWK to Sulindac
This is a "connection" page, showing publications ERNEST HAWK has written about Sulindac.
Connection Strength
0.566
-
Sulindac plus a phospholipid is effective for polyp reduction and safer than sulindac alone in a mouse model of colorectal cancer development. BMC Cancer. 2020 Sep 10; 20(1):871.
Score: 0.181
-
NSAID trials, sporadic adenomas, and conservative inferences. Gastroenterology. 1996 Feb; 110(2):654-5.
Score: 0.131
-
Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila). 2008 Jun; 1(1):32-8.
Score: 0.077
-
Ursodeoxycholate/Sulindac combination treatment effectively prevents intestinal adenomas in a mouse model of polyposis. Gastroenterology. 2004 Sep; 127(3):838-44.
Score: 0.060
-
Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis. Clin Cancer Res. 2000 Jan; 6(1):78-89.
Score: 0.043
-
Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol. 1999; 470:45-53.
Score: 0.040
-
Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis. 1996 Jul; 17(7):1435-8.
Score: 0.034